☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
sanofi
Sanofi Releases P-III (HERCULES) Data of Tolebrutinib (BTKi) for non-relapsing Secondary Progressive MS (nrSPMS)
September 4, 2024
Sanofi Publishes the P-III (XTEND-Kids) Study Data of Altuviiio to Treat Children with Severe Hemophilia A in the NEJM
July 18, 2024
PharmaShots Weekly Snapshots (July 01 – July 05, 2024)
July 5, 2024
Sanofi Reports the P-II Study Data of Frexalimab for the Treatment of Multiple Sclerosis
July 1, 2024
Sanofi Reports the P-II Study Data of Riliprubart to Treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
June 26, 2024
Sanofi Highlights the P-III (IMROZ) Study Data of Sarclisa for Newly Diagnosed Transplant-Ineligible Multiple Myeloma
June 4, 2024
Load more...
Back to Home